NN Group (2NN0) Q2 2026 Earnings Report

The call presented multiple strong operational and capital highlights: OCG growth (+5% to EUR 1.1bn), improved solvency (224%) after bank exclusion, clear delivery from the Future Ready AI/efficiency program, robust European commercial momentum (VNB +14% in Europe), strong DC inflows and AUM growth, improved Non-life profitability (combined ratio ~90.5%) and higher shareholder returns (interim dividend +12%). Offsetting these positives are localized but material challenges: weaker sales dynamics and lower CSM release in Japan, an expected drop in bancassurance volumes in Greece, regulatory fee pressure in Czechia, elevated disability claims and provisioning, and market/FX headwinds that reduced solvency by ~5 percentage points. On balance, the strengths—especially diversified, capital-generative growth, effective cost-savings from Future Ready, and strong capital-return discipline—meaningfully outweigh the identified headwinds, though some region-specific risks will require ongoing monitoring.

NN reiterated that 2026 operating capital generation (OCG) guidance is broadly flat but H1 OCG came in at EUR 1.1 billion (+5% YoY) leaving some upside (H2 expected in line with H1), with Group solvency strengthened to 224% (Netherlands Life 213%) and the 200% reference for excess-capital decisions unchanged. The Future Ready program remains on track: EUR 450 million of total investment, ~70% invested by June and ~65% of the target annual savings delivered toward EUR 200 million of annual benefits by end‑2027 (≈EUR 180 million expense savings), while retail AI straight‑through processing is ~35% (plus 15% from NN Bank) and targeting near 100% in H2; free cash flow was EUR 922 million in H1 (+7% YoY), FY26 expected broadly in line with EUR 1.6 billion (target >EUR 1.8 billion by 2028) and cash capital EUR 1.7 billion. Capital‑return guidance was reiterated (interim dividend EUR 1.55, +12% YoY; annual share buyback program EUR 350 million; >EUR 15 billion total capital return by 2028, versus >EUR 11 billion returned since IPO); commercial/segment targets highlighted include Europe VNB +14% (group VNB +16%), Europe AUM EUR 50 billion, Netherlands DC AUM EUR 48 billion (+13%), Non‑life gross written premium +6% with a combined ratio 90.5% (vs 91–93% guide), Europe OCG target EUR 600 million and Netherlands Non‑life OCG target EUR 475 million by 2028 (with ≥80% free‑cash‑flow conversion), and Japan actions (reinsurance adding ~EUR 240 million local equity) to preserve remittance and solvency under ICS despite Japan VNB down ~5% in H1 (cc).